Intrinsic value of Halozyme Therapeutics - HALO

Previous Close

$17.10

  Intrinsic Value

$465.16

stock screener

  Rating & Target

str. buy

+999%

Previous close

$17.10

 
Intrinsic value

$465.16

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of HALO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  507
  784
  1,172
  1,700
  2,399
  3,298
  4,427
  5,813
  7,480
  9,448
  11,732
  14,343
  17,288
  20,570
  24,186
  28,134
  32,409
  37,002
  41,906
  47,115
  52,621
  58,419
  64,504
  70,874
  77,527
  84,464
  91,689
  99,206
  107,022
  115,145
Variable operating expenses, $m
  159
  245
  367
  532
  751
  1,032
  1,386
  1,819
  2,341
  2,957
  3,672
  4,489
  5,411
  6,438
  7,570
  8,806
  10,144
  11,582
  13,117
  14,747
  16,470
  18,285
  20,190
  22,183
  24,266
  26,437
  28,699
  31,051
  33,498
  36,040
Fixed operating expenses, $m
  192
  196
  201
  205
  210
  214
  219
  224
  229
  234
  239
  244
  249
  255
  261
  266
  272
  278
  284
  291
  297
  303
  310
  317
  324
  331
  338
  346
  353
  361
Total operating expenses, $m
  351
  441
  568
  737
  961
  1,246
  1,605
  2,043
  2,570
  3,191
  3,911
  4,733
  5,660
  6,693
  7,831
  9,072
  10,416
  11,860
  13,401
  15,038
  16,767
  18,588
  20,500
  22,500
  24,590
  26,768
  29,037
  31,397
  33,851
  36,401
Operating income, $m
  156
  342
  604
  963
  1,438
  2,052
  2,822
  3,770
  4,910
  6,257
  7,821
  9,610
  11,628
  13,876
  16,355
  19,062
  21,993
  25,142
  28,505
  32,078
  35,854
  39,831
  44,004
  48,373
  52,937
  57,696
  62,652
  67,809
  73,171
  78,744
EBITDA, $m
  157
  343
  606
  965
  1,441
  2,056
  2,828
  3,777
  4,919
  6,268
  7,835
  9,627
  11,648
  13,901
  16,384
  19,096
  22,031
  25,186
  28,556
  32,134
  35,917
  39,901
  44,082
  48,458
  53,030
  57,797
  62,762
  67,928
  73,299
  78,882
Interest expense (income), $m
  4
  13
  16
  31
  52
  81
  118
  167
  228
  303
  394
  500
  624
  766
  925
  1,103
  1,299
  1,513
  1,745
  1,993
  2,259
  2,541
  2,840
  3,154
  3,484
  3,829
  4,189
  4,565
  4,957
  5,364
  5,788
Earnings before tax, $m
  143
  326
  573
  911
  1,358
  1,933
  2,655
  3,541
  4,606
  5,863
  7,320
  8,985
  10,862
  12,951
  15,252
  17,763
  20,480
  23,397
  26,512
  29,818
  33,312
  36,991
  40,850
  44,890
  49,108
  53,507
  58,087
  62,852
  67,807
  72,956
Tax expense, $m
  39
  88
  155
  246
  367
  522
  717
  956
  1,244
  1,583
  1,977
  2,426
  2,933
  3,497
  4,118
  4,796
  5,529
  6,317
  7,158
  8,051
  8,994
  9,987
  11,030
  12,120
  13,259
  14,447
  15,683
  16,970
  18,308
  19,698
Net income, $m
  105
  238
  419
  665
  991
  1,411
  1,938
  2,585
  3,363
  4,280
  5,344
  6,559
  7,929
  9,454
  11,134
  12,967
  14,950
  17,080
  19,354
  21,767
  24,318
  27,003
  29,821
  32,769
  35,849
  39,060
  42,403
  45,882
  49,499
  53,258

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  291
  449
  672
  975
  1,376
  1,891
  2,538
  3,333
  4,289
  5,417
  6,727
  8,224
  9,913
  11,795
  13,868
  16,132
  18,583
  21,217
  24,029
  27,016
  30,173
  33,497
  36,986
  40,639
  44,453
  48,431
  52,574
  56,884
  61,366
  66,024
Adjusted assets (=assets-cash), $m
  291
  449
  672
  975
  1,376
  1,891
  2,538
  3,333
  4,289
  5,417
  6,727
  8,224
  9,913
  11,795
  13,868
  16,132
  18,583
  21,217
  24,029
  27,016
  30,173
  33,497
  36,986
  40,639
  44,453
  48,431
  52,574
  56,884
  61,366
  66,024
Revenue / Adjusted assets
  1.742
  1.746
  1.744
  1.744
  1.743
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
  1.744
Average production assets, $m
  6
  9
  14
  20
  29
  40
  53
  70
  90
  113
  141
  172
  207
  247
  290
  338
  389
  444
  503
  565
  631
  701
  774
  850
  930
  1,014
  1,100
  1,190
  1,284
  1,382
Working capital, $m
  -5
  -7
  -11
  -15
  -22
  -30
  -40
  -52
  -67
  -85
  -106
  -129
  -156
  -185
  -218
  -253
  -292
  -333
  -377
  -424
  -474
  -526
  -581
  -638
  -698
  -760
  -825
  -893
  -963
  -1,036
Total debt, $m
  152
  295
  495
  768
  1,128
  1,592
  2,175
  2,890
  3,750
  4,766
  5,945
  7,292
  8,812
  10,506
  12,372
  14,409
  16,615
  18,985
  21,516
  24,204
  27,046
  30,038
  33,178
  36,465
  39,899
  43,479
  47,207
  51,086
  55,120
  59,312
Total liabilities, $m
  262
  404
  605
  877
  1,238
  1,702
  2,285
  3,000
  3,860
  4,875
  6,054
  7,402
  8,922
  10,615
  12,481
  14,519
  16,725
  19,095
  21,626
  24,314
  27,156
  30,148
  33,288
  36,575
  40,008
  43,588
  47,317
  51,196
  55,229
  59,421
Total equity, $m
  29
  45
  67
  97
  138
  189
  254
  333
  429
  542
  673
  822
  991
  1,179
  1,387
  1,613
  1,858
  2,122
  2,403
  2,702
  3,017
  3,350
  3,699
  4,064
  4,445
  4,843
  5,257
  5,688
  6,137
  6,602
Total liabilities and equity, $m
  291
  449
  672
  974
  1,376
  1,891
  2,539
  3,333
  4,289
  5,417
  6,727
  8,224
  9,913
  11,794
  13,868
  16,132
  18,583
  21,217
  24,029
  27,016
  30,173
  33,498
  36,987
  40,639
  44,453
  48,431
  52,574
  56,884
  61,366
  66,023
Debt-to-equity ratio
  5.230
  6.560
  7.370
  7.880
  8.200
  8.420
  8.570
  8.670
  8.740
  8.800
  8.840
  8.870
  8.890
  8.910
  8.920
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.980
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  105
  238
  419
  665
  991
  1,411
  1,938
  2,585
  3,363
  4,280
  5,344
  6,559
  7,929
  9,454
  11,134
  12,967
  14,950
  17,080
  19,354
  21,767
  24,318
  27,003
  29,821
  32,769
  35,849
  39,060
  42,403
  45,882
  49,499
  53,258
Depreciation, amort., depletion, $m
  1
  1
  1
  2
  3
  4
  5
  7
  9
  11
  14
  17
  21
  25
  29
  34
  39
  44
  50
  57
  63
  70
  77
  85
  93
  101
  110
  119
  128
  138
Funds from operations, $m
  105
  239
  420
  667
  994
  1,415
  1,944
  2,592
  3,372
  4,291
  5,358
  6,577
  7,950
  9,479
  11,163
  13,001
  14,989
  17,125
  19,404
  21,824
  24,381
  27,073
  29,898
  32,854
  35,942
  39,161
  42,513
  46,001
  49,627
  53,396
Change in working capital, $m
  -2
  -2
  -3
  -5
  -6
  -8
  -10
  -12
  -15
  -18
  -21
  -24
  -27
  -30
  -33
  -36
  -38
  -41
  -44
  -47
  -50
  -52
  -55
  -57
  -60
  -62
  -65
  -68
  -70
  -73
Cash from operations, $m
  107
  241
  424
  672
  1,000
  1,423
  1,954
  2,605
  3,387
  4,309
  5,379
  6,600
  7,976
  9,509
  11,196
  13,036
  15,027
  17,166
  19,448
  21,871
  24,431
  27,125
  29,953
  32,912
  36,002
  39,224
  42,578
  46,069
  49,698
  53,469
Maintenance CAPEX, $m
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -11
  -14
  -17
  -21
  -25
  -29
  -34
  -39
  -44
  -50
  -57
  -63
  -70
  -77
  -85
  -93
  -101
  -110
  -119
  -128
New CAPEX, $m
  -2
  -3
  -5
  -6
  -8
  -11
  -14
  -17
  -20
  -24
  -27
  -31
  -35
  -39
  -43
  -47
  -51
  -55
  -59
  -63
  -66
  -70
  -73
  -76
  -80
  -83
  -87
  -90
  -94
  -97
Cash from investing activities, $m
  -2
  -4
  -6
  -7
  -10
  -14
  -18
  -22
  -27
  -33
  -38
  -45
  -52
  -60
  -68
  -76
  -85
  -94
  -103
  -113
  -123
  -133
  -143
  -153
  -165
  -176
  -188
  -200
  -213
  -225
Free cash flow, $m
  104
  237
  418
  664
  990
  1,410
  1,936
  2,583
  3,360
  4,276
  5,340
  6,555
  7,924
  9,448
  11,128
  12,960
  14,942
  17,072
  19,345
  21,758
  24,308
  26,993
  29,810
  32,758
  35,837
  39,047
  42,390
  45,868
  49,485
  53,243
Issuance/(repayment) of debt, $m
  27
  143
  200
  273
  361
  464
  583
  715
  860
  1,015
  1,179
  1,348
  1,520
  1,693
  1,866
  2,037
  2,206
  2,370
  2,531
  2,688
  2,842
  2,992
  3,140
  3,287
  3,433
  3,580
  3,728
  3,879
  4,033
  4,192
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  27
  143
  200
  273
  361
  464
  583
  715
  860
  1,015
  1,179
  1,348
  1,520
  1,693
  1,866
  2,037
  2,206
  2,370
  2,531
  2,688
  2,842
  2,992
  3,140
  3,287
  3,433
  3,580
  3,728
  3,879
  4,033
  4,192
Total cash flow (excl. dividends), $m
  131
  380
  618
  937
  1,351
  1,873
  2,519
  3,298
  4,220
  5,292
  6,519
  7,902
  9,444
  11,142
  12,994
  14,997
  17,148
  19,442
  21,876
  24,446
  27,150
  29,985
  32,950
  36,045
  39,270
  42,627
  46,119
  49,748
  53,518
  57,436
Retained Cash Flow (-), $m
  -82
  -16
  -22
  -30
  -40
  -52
  -65
  -79
  -96
  -113
  -131
  -150
  -169
  -188
  -207
  -226
  -245
  -263
  -281
  -299
  -316
  -332
  -349
  -365
  -381
  -398
  -414
  -431
  -448
  -466
Prev. year cash balance distribution, $m
  261
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  31
  49
  76
  114
  165
  233
  320
  429
  564
  726
  916
  1,138
  1,391
  1,677
  1,995
  2,346
  2,729
  3,144
  3,589
  4,065
  4,570
  5,104
  5,667
  6,257
  6,875
  7,520
  8,193
  8,894
  9,623
  10,381
Cash available for distribution, $m
  310
  364
  596
  907
  1,310
  1,822
  2,454
  3,218
  4,124
  5,179
  6,388
  7,753
  9,275
  10,954
  12,787
  14,771
  16,903
  19,179
  21,595
  24,147
  26,834
  29,652
  32,601
  35,680
  38,889
  42,230
  45,704
  49,316
  53,070
  56,970
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  297
  333
  519
  746
  1,016
  1,322
  1,658
  2,012
  2,369
  2,715
  3,033
  3,308
  3,526
  3,677
  3,754
  3,754
  3,678
  3,532
  3,325
  3,068
  2,776
  2,460
  2,137
  1,817
  1,513
  1,232
  981
  763
  579
  429
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

FINANCIAL RATIOS  of  Halozyme Therapeutics (HALO)

Valuation Ratios
P/E Ratio -21.5
Price to Sales 15.1
Price to Book -69.2
Price to Tangible Book
Price to Cash Flow -44.3
Price to Free Cash Flow -41.8
Growth Rates
Sales Growth Rate 8.9%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 50%
Cap. Spend. - 3 Yr. Gr. Rate 8.4%
Financial Strength
Quick Ratio 12
Current Ratio 0
LT Debt to Equity -625%
Total Debt to Equity -678.1%
Interest Coverage -25
Management Effectiveness
Return On Assets -44.6%
Ret/ On Assets - 3 Yr. Avg. -36.4%
Return On Total Capital -74.1%
Ret/ On T. Cap. - 3 Yr. Avg. -73.8%
Return On Equity -1872.7%
Return On Equity - 3 Yr. Avg. -865.5%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 76.9%
Gross Margin - 3 Yr. Avg. 75.4%
EBITDA Margin -65.3%
EBITDA Margin - 3 Yr. Avg. -56.2%
Operating Margin -56.5%
Oper. Margin - 3 Yr. Avg. -53.7%
Pre-Tax Margin -69.4%
Pre-Tax Margin - 3 Yr. Avg. -61.3%
Net Profit Margin -70.1%
Net Profit Margin - 3 Yr. Avg. -61.5%
Effective Tax Rate -1%
Eff/ Tax Rate - 3 Yr. Avg. -0.3%
Payout Ratio 0%

HALO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the HALO stock intrinsic value calculation we used $317 million for the last fiscal year's total revenue generated by Halozyme Therapeutics. The default revenue input number comes from 2017 income statement of Halozyme Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our HALO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for HALO is calculated based on our internal credit rating of Halozyme Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Halozyme Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of HALO stock the variable cost ratio is equal to 31.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $188 million in the base year in the intrinsic value calculation for HALO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 10.5% for Halozyme Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Halozyme Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the HALO stock is equal to 9.7%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for HALO are equal to 1.2%.

Life of production assets of 10 years is the average useful life of capital assets used in Halozyme Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for HALO is equal to -0.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $208 million for Halozyme Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 136 million for Halozyme Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Halozyme Therapeutics at the current share price and the inputted number of shares is $2.3 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 41.42 24.58  sell
ABBV AbbVie 98.22 93.18  hold
LLY Eli Lilly 104.36 51.30  sell
JNJ Johnson&Johnso 132.48 126.96  hold
MRK Merck&Co 68.85 22.92  str.sell
FGEN FibroGen 60.55 2.53  str.sell

COMPANY NEWS

▶ Halozyme Therapeutics: 2Q Earnings Snapshot   [05:05AM  Associated Press]
▶ Halozyme Reports Second Quarter 2018 Results   [Aug-07-18 04:21PM  PR Newswire]
▶ Halozyme Therapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating   [May-24-18 03:00AM  Investor's Business Daily]
▶ Halozyme Therapeutics: 1Q Earnings Snapshot   [May-10-18 04:44PM  Associated Press]
▶ Halozyme Therapeutics tops Street 4Q forecasts   [Feb-20-18 04:49PM  Associated Press]
▶ First Eagle Reduces Halozyme Therapeutics Stake   [Feb-05-18 05:43PM  GuruFocus.com]
▶ First Eagle Fund of America 4th Quarter Commentary   [Jan-29-18 05:39PM  GuruFocus.com]
▶ Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92   [Jan-11-18 03:00AM  Investor's Business Daily]
▶ 3 Top Stocks Wall Street Is Overlooking   [Dec-26-17 10:30AM  Motley Fool]
▶ Analyst Recommendations for Alexion in December 2017   [Dec-11-17 09:02AM  Market Realist]
▶ Halozyme Therapeutics beats 3Q profit forecasts   [Nov-07-17 06:01PM  Associated Press]
▶ 3 Monster Stocks in the Making   [06:03AM  Motley Fool]
▶ 1 Great Biotech Stock You Have Never Heard Of   [Sep-29-17 11:34AM  Motley Fool]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.